Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more

Plus: IPO updates from Sunho, Rapport; Bicycle’s massive PIPE; Dyne’s opportunistic follow-on; and more

Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering

The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff

Aficamten appears to have slight edge over Camzyos in increasing peak oxygen uptake

Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more

Plus: LianBio promotes Pascal to CCO and updates from Ocuphire and ImmVira

Plus: FDA extends PDUFA for Daiichi’s quizartinib, and updates from AbbVie, Apellis and more

As blockbusters lose patent exclusivity, pharma believes nine-product portfolio has $25B long-term potential

BioCentury’s analysts look back at a year when industry took some slings and arrows but delivered breakthroughs, and predict what’ll be hot in 2023